Palisade Bio, Inc. (NASDAQ: PALI) has disclosed a notable increase in insider ownership following recent share acquisitions by Director Robert Baltera Jr. The transactions, detailed in a Form 4 filing submitted to the Securities and Exchange Commission, reflect a cumulative investment of $88,698 by the executive.
On July 8, 2026, Baltera Jr. initiated the purchases by acquiring 20,000 shares of the company's common stock. The weighted average price for this tranche was recorded at $1.9899 per share, with individual transaction prices fluctuating between $1.98 and $2.00. The following day, July 9, 2026, the director expanded his position further by purchasing an additional 25,000 shares. These subsequent shares were acquired at a weighted average price of $1.956 per share, with the execution prices ranging from $1.9298 to $1.98.
Following these acquisitions, Baltera Jr.'s direct ownership of Palisade Bio common stock totals 461,904 shares. The insider buying activity arrives as the stock has experienced significant volatility, evidenced by a beta coefficient of 1.51. Despite a 151% return over the trailing twelve-month period, valuation analysis suggests the shares may currently trade at a premium relative to fair value estimates.
Parallel to the insider transactions, Palisade Bio has achieved a key regulatory milestone. The U.S. Food and Drug Administration has granted clearance for the Investigational New Drug application for PALI-2108. This regulatory approval enables the company to proceed with the ASCENTRA-Phase 2 clinical trial, which is designed to evaluate the treatment in patients suffering from moderately to severely active ulcerative colitis.
The ASCENTRA-UC trial is structured to enroll up to 204 participants across clinical sites in North America and Europe. Patient enrollment is projected to commence in the second half of 2026, with primary efficacy data anticipated for release in the second half of 2027. The clinical development follows recent presentations of pharmacokinetic data for PALI-2108 at Digestive Disease Week 2026, which indicated that the active metabolite PALI-0008 rapidly achieved steady-state concentrations and maintained a favorable tissue-to-plasma exposure ratio.
Market reaction to these developments has included renewed analyst coverage. H.C. Wainwright has reaffirmed its Buy rating on Palisade Bio, maintaining a price target of $7.00. The company's board structure has also seen updates, with the appointment of Robert Baltera and Jordan Zwick to the Board of Directors, leveraging their biotech expertise to guide strategic initiatives.